We are proud to support Anal Cancer Awareness day. Named for the late Farrah Fawcett, our FAWCETT trial utilizes our Lm-based Antigen Delivery System in the fight against anal cancer.
Anal Cancer Awareness Day
Advaxis proudly supports:
Lm Technology™ leverages our Lm-based Antigen Delivery System™ which utilizes the efficiency of the entire immune system by teaching it to recognize the tumor as a threat, and by weakening the tumor’s defenses. Once educated, the immune system—specifically, its killer T cells—are enabled to do their job and work to destroy the cancer.
AIM2CERV is the only industry-sponsored phase 3 clinical study focused on cervical cancer in the world. Learn more.
Aiming to Prevent Cervical Cancer Recurrence
Advancing under a clinical development program between Amgen and Advaxis. MINE™ has the potential to provide patients with a truly customized approach to cancer treatment by stimulating an immune response against unique mutations, or neoantigens, contained in each patient’s tumor. Learn more.
With multiple clinical studies in cervical cancer underway, Advaxis is committed to supporting the cervical cancer community. Learn more.
Committed to the Cervical Cancer Patient Community